Topical tacrolimus in atopic dermatitis: Effects of ... - Helda - Helsinki.fi
Topical tacrolimus in atopic dermatitis: Effects of ... - Helda - Helsinki.fi
Topical tacrolimus in atopic dermatitis: Effects of ... - Helda - Helsinki.fi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>of</strong> one type <strong>of</strong> treatment can be better extended to cl<strong>in</strong>ical practice, have become<br />
necessary for chronic diseases such as asthma (Bjermer 2006). At present, no such<br />
studies have appeared on AD.<br />
Table 1. Studies on the most common treatments <strong>of</strong> AD <strong>in</strong>clud<strong>in</strong>g only those with<br />
ef<strong>fi</strong>cacy >50%.<br />
Treatment Ef<strong>fi</strong>cacy <strong>in</strong> placebo-controlled short-term<br />
studies ( < 6 months)<br />
<strong>Topical</strong><br />
steroids<br />
UV-light<br />
treatments<br />
Betamethasone dipropionate (Vanderploeg<br />
1976)<br />
Clobetasol propionate (Maloney et al. 1998)<br />
Desonide (Stalder et al. 1994)<br />
Halc<strong>in</strong>onide (Lupton et al. 1982)<br />
Hydrocortisone buteprate (Sears et al. 1997)<br />
Hydrocortisone valerate (Sefton et al. 1984)<br />
Fluticasone propionate (Lebwohl et al. 1996)<br />
Fluticasone propionate <strong>in</strong> ma<strong>in</strong>tenance therapy<br />
twice weekly (Berth-Jones et al. 2003)<br />
Broad band UVB (Jekler & Larkö 1988)<br />
Narrow band UVB, UVA (Reynolds et al. 2001)<br />
Ciclospor<strong>in</strong> 5 mg/kg (Munro et al. 1994, Salek et al. 1993,<br />
Sowden et al. 1991, van Joost et al. 1994,<br />
Wahlgren et al. 1990)<br />
Systemic<br />
steroids<br />
32<br />
Ef<strong>fi</strong>cacy <strong>in</strong> controlled long-term studies<br />
( � 6 months)<br />
Fluticasone propionate vs. vehicle <strong>in</strong><br />
ma<strong>in</strong>tenance therapy twice weekly (Hanif<strong>in</strong> et al.<br />
2002)<br />
Unavailable<br />
Unavailable Unavailable<br />
Methotrexate Unavailable Unavailable<br />
Azathiopr<strong>in</strong>e Unavailable Unavailable<br />
Tacrolimus<br />
o<strong>in</strong>tment<br />
Pimecrolimus<br />
cream<br />
0.03% <strong>in</strong> children (Schachner et al. 2005)<br />
0.03% <strong>in</strong> adults and children (Chapman et al.<br />
2005)<br />
0.1% and 0.03% <strong>in</strong> adults and children (Hanif<strong>in</strong><br />
et al. 2001, Paller et al. 2001)<br />
0.03%, 0.1%, and 0.3% <strong>in</strong> adults and children<br />
(Ruzicka et al. 1997, Boguniewicz et al. 1998)<br />
Adults (Eichen<strong>fi</strong>eld et al. 2002)<br />
Children (Ho et al. 2003)<br />
3 mg/kg vs. 5mg/kg (Zonneveld et al. 1996)<br />
Short courses vs. cont<strong>in</strong>uous (Harper et al. 2000)<br />
0.1% <strong>tacrolimus</strong> vs. hydrocortisone 17-butyrate/<br />
hydrocortisone (Reitamo et al. 2005)<br />
Pimecrolimus vs. vehicle <strong>in</strong> adults, flare control<br />
(Meurer et al. 2002, 2004)<br />
Pimecrolimus vs. vehicle <strong>in</strong> children, flare control<br />
(Wahn et al. 2002, Kapp et al. 2002, Papp et al.<br />
2004)<br />
Pimecrolimus vs. triamc<strong>in</strong>olone acetate /<br />
hydrocortisone (Luger et al. 2004) (No <strong>in</strong>tentionto-treat<br />
analysis)